Seres Therapeutics (MCRB)

• Market cap: $132M
• 1 day: 3.45%
• 5 days: 2.19%
• 1 month: 4.15%
• 3 months: -14.84%
• 6 months: -17.81%
• Year to date: -10.45%
• 1 year: -3.20%
• 5 years: -77.98%
• 10 years: -98.53%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Employees: 103

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

860% more call options, than puts

Call options by funds: $2.76M | Put options by funds: $287K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 18

4.66% less ownership

Funds ownership: 41.61% [Q3] → 36.94% (-4.66%) [Q4]

9% less funds holding

Funds holding: 76 [Q3] → 69 (-7) [Q4]

12% less capital invested

Capital invested by funds: $60M [Q3] → $52.5M (-$7.49M) [Q4]

44% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 16

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $0.75 1% downside
• Avg. target: $1 32% upside
• High target: $1.25 66% upside

2 analyst ratings

• positive: 1 50%
• neutral: 0 0%
• negative: 1 50%

Chardan Capital Keay Nakae 23% 1-year accuracy 16 / 70 met price target	66% upside $1.25	Buy Maintained	20 Mar 2025
Goldman Sachs Chris Shibutani 17% 1-year accuracy 2 / 12 met price target	1% downside $0.75	Sell Maintained	14 Mar 2025